Pharsight

Sensipar generic

Sensipar is a hyperparathyroidism and hypercalcemia treatment drug owned by Amgen, possessing the active ingredient cinacalcet hydrochloride. It was first authorized for market use on 08 March, 2004, and is available in tablet form for oral administration.

When will Sensipar generic be available?

The Sensipar generic is expected to be available after 22 September, 2026. This is due to the expiration of the last patent held on the drug, specifically patent number US9375405.

Sensipar uses

Sensipar is used to treat hyperparathyroidism and hypercalcemia. Its effectiveness is attributed to its active ingredient, cinacalcet hydrochloride, which helps manage calcium levels in the body.

Sensipar patent expiration

Sensipar is covered by two patents, with the last expiring on 22 September, 2026. More information about the Sensipar generic and the patents can be found below. Below are the details of the patent:

EPO Oppostions filed on Sensipar

Litigations filed on Sensipar

Sensipar dosage

Want to ask something?